New drug VT3989 takes on tough cancers in early trial
NCT ID NCT04665206
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new oral drug called VT3989, alone or with other cancer drugs, in people with advanced solid tumors, mesothelioma, or non-small cell lung cancer that hasn't responded to standard treatments. The trial has two phases: first, finding the safest dose, then expanding to see how well it works. About 434 participants will be enrolled across multiple sites.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- VT3989 (a drug taken by mouth), sometimes combined with other drugs like nivolumab, ipilimumab, osimertinib, or pemetrexed/carboplatin
- What this could lead to
- If successful, this could point toward a new treatment option for people with advanced solid tumors, mesothelioma, or lung cancer that hasn't responded to standard therapies.
- What could go wrong
- This is an early-phase trial (Phase 1/2) with a small number of participants, so the drug may not prove effective or may cause significant side effects. It's too early to know if it will lead to a widely available treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT MESOTHELIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Linear Clinical Research
RECRUITINGNedlands, Western Australia, 6009, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
M Health Fairview University of Minnesota Medical Center
RECRUITINGMinneapolis, Minnesota, 55455, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Monash Health
RECRUITINGClayton, Victoria, 3168, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NEXT Oncology
RECRUITINGSan Antonio, Texas, 78229, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Peter MacCullum Cancer Centre
RECRUITINGMelbourne, Victoria, 3000, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UCSF Helen Diller Family Comprehensive Cancer Center
RECRUITINGSan Francisco, California, 94158, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Chicago Medical Center
RECRUITINGChicago, Illinois, 60637, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Virginia Cancer Specialists, PC
RECRUITINGArlington, Virginia, 22201, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Chest-Injected drug drain Cancer's fluid trap?
- Can a Two-Pronged antibody boost Chemo's power against lung cancer?
- Fighting cancer wasting: can diet and exercise make olanzapine work better?
- Can a pill that starves tumors of oxygen help fight advanced cancer?
- Can a new drug shrink Hard-to-Treat solid tumors?
- Could a gene mutation predict immunotherapy success? virtual trial aims to find out